Targeting the Cancer Stem Cell Metabolism (preclinical stage)

Ruthenium-Catalyzed (RuCSC) Redox Isomerizations inside Living Cells. RuCSC inhibits CSC mitochondrial metabolism.

Our target population are patients with CSC-driven tumors, as the maintenance of these cancers depend on CSCs. We has focused on Pancreatic cancer as a model tumor, but this technology could be extended to other cancers (e.g., colon, lung, breast):

Ongoing: 1) Validating the technology in preclinical models of different tumors driven by CSCs; 2) In vivo safety, bioavailability and anti-cancer efficacy studies; 3) Efficacy of RuCSC in combination with SOC and other commercial drugs; 4) Decipher the mechanism of action of RuCSC and improved derivatives.